BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is the observed X-ray diffraction pattern of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (Form A) (upper trace) superimposed on the calculated powder X-ray diffraction pattern for Form A (y axis is linear counts per second; X in degrees 2 theta).

FIG. 2 is the observed powder X-ray diffraction pattern of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (Form A) (y axis is linear counts per second; X in degrees 2 theta).

FIG. 3 is the calculated powder X-ray diffraction pattern of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (Form A) (y axis is linear counts per second; X in degrees 2 theta).

FIG. 4 is the observed X-ray diffraction pattern of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (Form B) (upper trace) superimposed on the calculated powder X-ray diffraction pattern for Form B (y axis is linear counts per second; X in degrees 2 theta).

FIG. 5 is the observed powder X-ray diffraction pattern of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (Form B) (y axis is linear counts per second; X in degrees 2 theta).

FIG. 6 is the calculated powder X-ray diffraction pattern of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (Form B) (y axis is linear counts per second; X in degrees 2 theta).

FIG. 7 is the observed powder X-ray diffraction pattern of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (Form C) (y axis is linear counts per second; X in degrees 2 theta).

FIG. 8 is the observed powder X-ray diffraction pattern of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (Form D) (y axis is linear counts per second; X in degrees 2 theta).

FIG. 9 is the observed powder X-ray diffraction pattern of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (Form E) (y axis is linear counts per second; X in degrees 2 theta).

FIG. 10 is the ^{13}C NMR spectrum of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine Form B in the solid phase as measured by cross-polarization magic angle spinning (CPMAS) on a 4 mm BL Bruker wide-bore magic angle spinning (WB MAS) probe positioned in a 11.75 T spectrometer (Bruker Biospin, Inc.) corresponding to 125 MHz ^{13}C frequency.

FIG. 11 is a differential scanning calorimetry thermal profile of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (Form A).

FIG. 12 is a differential scanning calorimetry thermal profile of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (Form B).

FIG. 13 is a differential scanning calorimetry thermal profile of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (Form C).

FIG. 14 is a differential scanning calorimetry thermal profile of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (Form D).

FIG. 15 is a differential scanning calorimetry thermal profile of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (Form D).

FIG. 16 is a differential scanning calorimetry thermal profile of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (Form E).